Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: J Immunol. 2009 Nov 30;184(1):268–276. doi: 10.4049/jimmunol.0800924

Fig. 4. Anti-CD1d mAb reduces disease and enhances cytokines following virus infection in vivo.

Fig. 4

Male C57BL/6J WT or CD1d KO mice were infected with EMCV-D and followed as in Fig. 3. Results show individual animal data. A. Glucose tolerance test. B. Paralysis score. 50μg anti-CD1d mAb 1B1 or isotype control mAb, or 2μg α-galactosylceramide was given once / animal on day of infection, reducing diabetes (A.) and paralysis incidence of 6 week old mice (B.), measured at 7 days. Lines shown define hyperglycemia or values above baseline (defined as ‘1’ to show mice) of no paralysis (uninfected animals). The same groups of mice as shown in Fig. 4A,B were tested for serum cytokines. CD1d mAb could specifically induce elevated systemic Th1 cytokine levels. Results show individual animal day 7 serum p70 IL-12 (C.), IFN-γ (D.), and IFN-α (E.) ELISA data (lines indicate control uninfected and untreated animal baseline values).